Promoting Informed Decision Making: Hormone Replacement Therapy

  • Lori Bastian
  • Grace Couchman
  • Barbara K. Rimer
  • Colleen M. McBride
  • Linda Sutton
  • Ilene C. Siegler
Part of the Cancer Treatment and Research book series (CTAR, volume 97)


Although most gynecologists recognize the importance of discussing hormonal replacement therapy (HRT) with their patients, the controversies regarding the association between HRT and cancers, the questions about HRT use in women with a high risk of breast cancer, and the increasing number of women with breast cancer and menopausal symptoms make HRT a significant cancer issue. The scope is immense and growing as the “baby boom” generation approaches menopause. Currently, over 30 million woman are postmenopausal, and the average life expectancy after menopause is 30 years.[1] Despite the well-recognized benefits of HRT with regards to heart disease and osteoporosis, concern about the risk of cancer seems to prevent some physicians from prescribing HRT and many patients from using HRT.


Breast Cancer Breast Cancer Risk Endometrial Cancer Hormone Replacement Therapy Obstet Gynecol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Henderson BE, Bernstein L. Endogenous and Exogenous Hormonal Factors. In: Diseases of the Breast. Philadelphia: Lippincott-Raven Publishers, 1996.Google Scholar
  2. 2.
    Pilote L and Hlatky MA. Attitudes of women toward hormone therapy and prevention of heart disease. Am Heart J 1995; 129: 1237–1238.PubMedCrossRefGoogle Scholar
  3. 3.
    Sinclair HK, Bond CM, Taylor RJ. Hormone replacement therapy: a study of women’s knowledge and attitudes. British J Gen Prac. 1993;43:365–370.Google Scholar
  4. 4.
    Rothert M, Rovner D, Holmes M, et al. Women’s use of information regarding hormone replacement therapy. Research in Nursing and Health 1990; 13:355–66.PubMedCrossRefGoogle Scholar
  5. 5.
    Wolf AMD, Becker DM. Cancer Screening and Informed Patient Discussions. Truth and Consequences. Arch Intern Med 1996; 156:1069–72.PubMedCrossRefGoogle Scholar
  6. 6.
    McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103–115.PubMedCrossRefGoogle Scholar
  7. 7.
    Speroff L. Menopause and Hormone Replacement Therapy. Clinics in Geriatric Medicine 1993;9:33–55.PubMedGoogle Scholar
  8. 8.
    Ettinger B, Friedman GD, Bush T, Quesenberry CP. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996; 87:6–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses’ Health Study. N Engl J Med 1991;325:756–62.PubMedCrossRefGoogle Scholar
  10. 10.
    Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in uses of estrogen replacement therapy. Arch Intern Med 1991;151:75–78.PubMedCrossRefGoogle Scholar
  11. 11.
    Grady D, Rubin S, Petitti D, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016–1037.PubMedGoogle Scholar
  12. 12.
    Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular mortality in women over 50: The Framingham Study. N Engl J Med 1985;313:1038–43.PubMedCrossRefGoogle Scholar
  13. 13.
    Barrett-Connor E. Prevalence, Initiation, and Continuation of Hormone Replacement Therapy. J Women’s Health 1995;4:143–148.Google Scholar
  14. 14.
    Hemminiki E, Brambilla DJ, McKinley SM, Posner JG. Use of estrogens among middleaged Massachusetts women. Ann Pharmacother 1991; 25:418–20.Google Scholar
  15. 15.
    Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA 1989;261:2095–2100.PubMedCrossRefGoogle Scholar
  16. 16.
    Harris RB, Reddy VM, King A, et al. Are women using postmenopausal estrogens? A community Survey. Am J Public Health 1990;80:1266–68.PubMedGoogle Scholar
  17. 17.
    Hemminki E, Kennedy DL, Baum C, et al. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974–1986. Am J Public Health 1988;78:1479–1481.PubMedGoogle Scholar
  18. 18.
    Matthews KA, Kuller LH, Wing RR, Mellahn EN, Plantinga P. Prior to use of Estrogen Replacement Therapy, are Users Healthier than Nonusers? Am J Epidemiol 1996; 143:971–8.PubMedGoogle Scholar
  19. 19.
    Ferguson KJ, Hoegh C, Johnson S. Estrogen Replacement Therapy. A survey of women’s knowledge and attitudes. Arch Intern Med 1989; 149: 133–136.PubMedCrossRefGoogle Scholar
  20. 20.
    U.S. Preventive Services Task Force. Guide to clinical preventive-services: report of the U.S. Preventive Services Task Force. 2nd ed. 1996, Williams and Wilkins, Baltimore Md. Postmenopausal Hormone Prophylaxis, pps. 829–43.Google Scholar
  21. 21.
    Nabulsi AA, Folsom AR, White, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328:1069–1075.PubMedCrossRefGoogle Scholar
  22. 22.
    Finucane FF, Madans JH, Bush TL, et al. Decreased risk of stroke among postmenopausal hormone users. Results from s national cohort. Arch Intern Med 1993; 153:73–79.Google Scholar
  23. 23.
    Barrett-Connor E. Post-menopausal estrogens and prevention bias. Ann Intern Med 1991;115:455–456.PubMedGoogle Scholar
  24. 24.
    Petitti DB. Coronary heart disease and estrogen replacement therapy: can compliance bias explain the results of observational studies? Ann Epidemiol 1994;4:115–118.PubMedCrossRefGoogle Scholar
  25. 25.
    Cauley JA, Cummings SR, Black DM, et al. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990; 163:1438–44.PubMedGoogle Scholar
  26. 26.
    Hammond C, Jelovsek F, Lee K et al. Effects of long-term estrogen replacement therapy. Am J Obstet Gynecol 1979; 133:537–547.PubMedGoogle Scholar
  27. 27.
    Grady D. Hormone Therapy and the Risk of Cancer, In: Wenger N, Speroff L, Packard B, eds. Cardiovascular Health and Disease in Women. Le Jacq Communications, Inc. Greenwich, CT, 1993:199–211.Google Scholar
  28. 28.
    Grady D, Gebretsadik T, Kerlikowske K, Emster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995; 85:304–313.PubMedCrossRefGoogle Scholar
  29. 29.
    Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins: Use patterns over time. Obstet Gynecol 1985; 65:441–446.PubMedGoogle Scholar
  30. 30.
    Paganini-Hill A, Ross R, Henderson B. Endometrial cancer and patterns of use of oestrogen replacement therapy: A cohort study. Br J Cancer 1989; 59:445–447.PubMedGoogle Scholar
  31. 31.
    Shapiro S, Kaufman D, Slone E, et al. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. N Engl J Med 1980; 303:485–89.PubMedCrossRefGoogle Scholar
  32. 32.
    Antunes C, Stolley P, Rosenshein N et al. Endometrial cancer and estrogen use. N Engl J Med 1979; 300:9–13.PubMedCrossRefGoogle Scholar
  33. 33.
    Collins J, Donner A, Allen LH, Adams U. Oestrogen use and survival in endometrial cancer. Lancet 1980; 2:961–964.PubMedCrossRefGoogle Scholar
  34. 34.
    Horowitz RI, Feinstein AR, Horowitz SM, Robroy SJ. Necropsy diagnosis of endometrial cancer and detection bias in case/control studies. Lancet 1981;1:66–68.CrossRefGoogle Scholar
  35. 35.
    Rubin G, Peterson H, Lee N, Maes E, Wingo P, Becker S. Estrogen replacement therapy and the risk of endometrial cancer: Remaining controversies. Am J Obstet Gynecol 1990; 162:148–54.PubMedGoogle Scholar
  36. 36.
    Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman E. Estrogen replacement therapy: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54:74–79.PubMedCrossRefGoogle Scholar
  37. 37.
    Hammond C, Jelovsek F, Lee K, Creasman W, parker R. Effects of long-term estrogen replacement therapy. 11. Neoplasia. Am J Obstet Gynecol 1979; 133:537–47.PubMedGoogle Scholar
  38. 38.
    Gambrell RD. Prevention of Endometrial Cancer with progestogens. Maturitas 1986;8: 159–68.PubMedCrossRefGoogle Scholar
  39. 39.
    Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogen alone or in conjunction with progestogens: results of a prospective study. Br Med J 1989; 298:147–151.Google Scholar
  40. 40.
    Voigt LF, Weiss NS, Chu J, et al. Progestogen supplementation of erogenous oestrogen and risk of endometrial cancer. Lancet 1991;338:274–77.PubMedCrossRefGoogle Scholar
  41. 41.
    Jick S, Walker A, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993; 4:20–24.PubMedCrossRefGoogle Scholar
  42. 42.
    Brinton L, Hoover R. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues. Obstet Gynecol 1993; 81:265–271.PubMedGoogle Scholar
  43. 43.
    Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone: the Menopause Study group. Am J Obstet Gynecol 1994; 170:1213–1223.PubMedGoogle Scholar
  44. 44.
    Writing group of the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on Heart disease risk factors in postmenopausal women. JAMA 1995; 273:199–208.CrossRefGoogle Scholar
  45. 45.
    Speroff L. Postmenopausal hormone therapy and breast cancer. Obstet Gynecol. 1996; 87:44S–54S.PubMedCrossRefGoogle Scholar
  46. 46.
    Gambrell RD. Hormone replacement therapy and breast cancer risk. Arch Fam Med 1996; 5:341–348.PubMedCrossRefGoogle Scholar
  47. 47.
    Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epi Review 1993; 15(1): 36–47.Google Scholar
  48. 48.
    Bernstein L, Ross RK. Endogenous hormones and Breast cancer risk. Epi Review 1993; 15(1):48–65.Google Scholar
  49. 49.
    Armstrong BK. Oestrogen therapy after menopause: boon or bane? Med J Aust. 1988; 148:213–214.PubMedGoogle Scholar
  50. 50.
    Steinberg KK, Thacker SB, Smith J, et al. A meta-analysis of the effect of estrogen replacement therapy and breast cancer. JAMA 1991; 265:1985–1990.PubMedCrossRefGoogle Scholar
  51. 51.
    Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151:67–72.PubMedCrossRefGoogle Scholar
  52. 52.
    Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras A, et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet-Gynecol 1992;79:286–294.PubMedGoogle Scholar
  53. 53.
    Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol. 1993;168: 1473–1480.PubMedGoogle Scholar
  54. 54.
    Nachtigall LE, Smilen SW, Nachfigall RD, Nachtigall RH, Nachtigall LE. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992; 80:827–830.PubMedGoogle Scholar
  55. 55.
    Newcomb PA, Longnecker MP, Storer BE, et al. Long-term Hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epi 1995; 142:788–95.Google Scholar
  56. 56.
    Schairier C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer. Cancer Causes Control. 1994; 5:491–500.CrossRefGoogle Scholar
  57. 57.
    Stanford JL, Weiss NS, Voigt LF et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274:137–142.PubMedCrossRefGoogle Scholar
  58. 58.
    Colditz GA, Hankinson SE, Hunter DJ et al. The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal women. New Engl J Med. 1995; 332:1589–93.PubMedCrossRefGoogle Scholar
  59. 59.
    Harding C, Ynow WF, Faragher EG, Baildam A, Bundred NJ. Hormone replacement therapy and tumor grade in beast cancer: prospective study in a screening unit. BMJ 1996; 312:46–47.Google Scholar
  60. 60.
    Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK. Risk factors for in situ breast cancer. Cancer Epidemiology, Biomarkers and Prevention. 1996; 5:962–965.Google Scholar
  61. 61.
    Key T, Pike M. The role of oestrogens and progestogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24:29–43.PubMedCrossRefGoogle Scholar
  62. 62.
    Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer. 1988; 42:832–38.PubMedCrossRefGoogle Scholar
  63. 63.
    Bergkvist L, Adami HO. Persson I, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol. 1989; 130: 221–228.PubMedGoogle Scholar
  64. 64.
    Gambrell RD, Maier RC, Sanders Bl. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol. 1983; 62: 435–443.PubMedGoogle Scholar
  65. 65.
    Smith HO, Kammerer-Doak DN, Barbo DM, Saito GE. Hormone replacement therapy in the menopause: A pro opinion. Cancer J Clin 1996; 46:343–363.Google Scholar
  66. 66.
    Adami HO, Persson I. Hormone replacement therapy and breast cancer: A remaining controversy? JAMA 1995; 274:178–79.PubMedCrossRefGoogle Scholar
  67. 67.
    Cust NV, Gangar KF, Hillard TC, Whitehead NH. A risk-benefit assessment of Estrogen therapy in postmenopausal women. Drug Safety 1990; 5:345–358.PubMedGoogle Scholar
  68. 68.
    Cramer DW, Devasa SS, Welch WR. Trends in the incidence of endometrioid and clearcell cancers of the ovary in the United States. Am J Epi. 1981; 114:201–208.Google Scholar
  69. 69.
    Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. Reproductive experiences and family history. J Natl Cancer Inst. 1983; 71:711–716.PubMedGoogle Scholar
  70. 70.
    Jensen OM. Different age and sex relationships for cancer of subsites of the large bowel. Br J Cancer 1984; 50:825–829.PubMedGoogle Scholar
  71. 71.
    Potter JD. Hormones and colon cancer. J Natl Cancer Inst 1995; 87(14): 1039–40.PubMedCrossRefGoogle Scholar
  72. 72.
    McMichel AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: A review and hypothesis. J Natl Cancer Inst 1980; 65:1201–1207.Google Scholar
  73. 73.
    Fraumeni JF, Lloyd JW, Smith EM, et al. Cancer mortality among nuns: Role of marital status in etiology of neoplastic disease in women. J Natl Cancer Inst 1969; 42:455–468.PubMedGoogle Scholar
  74. 74.
    Potter JD, Slattery NM, Bostick RM, Gapstur SM. Colon Cancer: A review of the epidemiology. Epi Reviews 1993; 15(2):499–530.Google Scholar
  75. 75.
    American Cancer Society: Cancer Facts and Figures-1995. Atlanta. ACS.Google Scholar
  76. 76.
    Fumer SE, Dacis PG, Nelsom RI, et al. A case-control study of large bowel cancer and hormone exposure in women. Cancer Res 1989; 49:4936–4940.Google Scholar
  77. 77.
    Chute CG, Willett WD, Colditz GA, et al. A prospective study of reproductive history and exogenous estrogens on the risk of colorectal cancer in women. Epidemiology 1991; 2:201–207.PubMedCrossRefGoogle Scholar
  78. 78.
    Gerhardsson de VM, London S. Reproductive factors: Exogenous female hormones, and colorectal cancer by subsite. Cancer Causes Control 1992; 3:355–360.CrossRefGoogle Scholar
  79. 79.
    Jacobs EJ, White E, Wiss NS. Exogenous hormones, reproductive history, and colon cancer. Cancer Causes Control 1994; 5:359–366.PubMedCrossRefGoogle Scholar
  80. 80.
    Bostick RM, Potter JD, Kushi LH, et al. Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women. Cancer Causes Control 1994; 5:38–52.PubMedCrossRefGoogle Scholar
  81. 81.
    Newcomb PA Storer BE. Postmenopausal Hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995; 87:1067–71.PubMedCrossRefGoogle Scholar
  82. 82.
    Davis FG, Fumer SE, Persky V, et al. The influence of parity and erogenous female hormones on the risk of colorectal cancer. Int J Cancer 1989; 43:587–590.PubMedCrossRefGoogle Scholar
  83. 83.
    Adami HO, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44:833–839.PubMedCrossRefGoogle Scholar
  84. 84.
    Peters RK, Pike MC, Chang WW, et al. Reproductive factors and colon cancers. Br J Cancer 1990; 61:741–748.PubMedGoogle Scholar
  85. 85.
    Wu-Williams AH, Lee M, Whitemore AS, et al. Reproductive factors and colorectal cancer risk among Chinese females. Cancer Res 1991; 51:2307–2311.PubMedGoogle Scholar
  86. 86.
    Pisch HA, Howe GR. Menopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epidemiol Biomarkers 1995; 4:21–28.Google Scholar
  87. 87.
    Creasman W, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol. 1986; 67:326–330.PubMedGoogle Scholar
  88. 88.
    Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990; 36:189–191.PubMedCrossRefGoogle Scholar
  89. 89.
    Buller RE. Hormone replacement therapy following gynecologic cancer. Postgrad Obstet Gynecol 1993; 13:1–5.Google Scholar
  90. 90.
    Runowicz CD. Hormone replacement therapy in cancer survivors: A con opinion. Cancer J Clin 1996; 46:365–373.CrossRefGoogle Scholar
  91. 91.
    Cobleigh MA, Berris R-F, Bush T, et al. Estrogen replacement therapy in breast cancer survivors: A time for change. JAMA 1994; 272: 540–45.PubMedCrossRefGoogle Scholar
  92. 92.
    DiSala PJ, Creasman WT, Odicino F, et al. Hormone replacement therapy in breast cancer. Lancet 1993; 342:1232.Google Scholar
  93. 93.
    Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993; 165:372–75.PubMedCrossRefGoogle Scholar
  94. 94.
    Eden JA, Bush T, Nand S, Wren BG. A case-control study of combined-continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause. 1995; 2:67–72.CrossRefGoogle Scholar
  95. 95.
    McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J. 1991; 303:435–437.CrossRefGoogle Scholar
  96. 96.
    Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852–856.PubMedCrossRefGoogle Scholar
  97. 97.
    Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115:860–864.PubMedGoogle Scholar
  98. 98.
    Rossouw JE, Finnegan LP, Harlan WR, Pinn VW, et al. The Evolution of the Women’s Health Initiative: Perspectives from the NIH. JAMA 1995; 50(2):50–55.Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Lori Bastian
    • 1
  • Grace Couchman
    • 1
  • Barbara K. Rimer
    • 1
  • Colleen M. McBride
    • 1
  • Linda Sutton
    • 1
  • Ilene C. Siegler
    • 1
  1. 1.Center Durham VA Medical CenterDuke University MedicalDurham

Personalised recommendations